Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What Happens on May 31

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Jun 04, 2021 3:53pm

191 Views

Post# 33331639

RE:RE:RE:What Happens on May 31

The number of shares outstanding is still 45.5million, so Holdings hasn't been included, and therefore the patents' value hasn't been included in the MC either.

123ABC wrote:

Forestview wrote: Actually just heard from Dan. So, the MC will increase as it absorbs AH. How the market reacts will drive share price. Hopefully this is the last hurdle holding this stock down.

Looks like MC is decreasing